Springer Nature OA
open access
CC BY 4.0
Pharmacological treatment of MASH
Metabolic dysfunction-associated steatotic liver disease (MASLD) includes a spectrum of progressive liver conditions ranging from isolated steatosis to metabolic dysfunction-associated steatohepatitis (MASH), advanced fibrosis and cirrhosis. Currently, MASLD is the leading cause of chronic liver dis
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Non-pharmacological treatment of MASLD#1148615
- Imaging of MASLD: clinical standards and novel methods#1148617
- SAT-163 Inflammation-associated gene expression profiles distinguishing significant fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD): evidence from a Turkish patient cohort#309411
- Screening for MASLD-related Advanced Fibrosis in Type 2 Diabetes#834735
- Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)#394736
Record · ID 1148616
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive